Get started
Author

Ravindra Uppaluri

Observed names: R Uppaluri, R. Uppaluri, Ravi Uppaluri, Uppaluri, Ravindra
Observed institutions: Brigham and Women's Hospital, University of Minnesota, Beth Israel Deaconess Medical Center, Harvard University, Inserm, Carleton College, Washington University in St. Louis, Istituto Superiore di Sanità, Institut Gustave Roussy, University of California San Diego, Massachusetts General Hospital, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, John Cochran VA Medical Center, Innate Pharma (France), Dana-Farber Brigham Cancer Center, Alvin J. Siteman Cancer Center, Stanford University
ORCID: 0000-0001-5988-6828
Observed ORCID: 0000-0001-5988-6828
OpenAlex ID: A5026020571
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012 · Hirokazu Matsushita, Matthew D. Vesely, et al. · Nature · 1,288
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
2019 · Ezra E. W. Cohen, R. Bryan Bell, et al. · Journal for ImmunoTherapy of Cancer · 722
PDF
A critical function for type I interferons in cancer immunoediting
2005 · Gavin P Dunn, Allen T Bruce, et al. · Nature Immunology · 607
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
2025 · Ravindra Uppaluri, Robert I. Haddad, et al. · New England Journal of Medicine · 429
Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy
2022 · Adrienne M. Luoma, Shengbao Suo, et al. · Cell · 388
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
2020 · Ravindra Uppaluri, Katie M. Campbell, et al. · Clinical Cancer Research · 387
PDF
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
2020 · Jonathan D. Schoenfeld, Glenn J. Hanna, et al. · JAMA Oncology · 365
PDF
Cancer immunoediting by the innate immune system in the absence of adaptive immunity
2012 · Timothy O’Sullivan, Robert Saddawi-Konefka, et al. · The Journal of Experimental Medicine · 348
PDF
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
2018 · Israel Cañadas, Rohit Thummalapalli, et al. · Nature Medicine · 313
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
2016 · Tanner M. Johanns, Christopher A. Miller, et al. · Cancer Discovery · 289
PDF
Frameshift events predict anti–PD-1/L1 response in head and neck cancer
2018 · Glenn J. Hanna, Patrick Lizotte, et al. · JCI Insight · 276
PDF
Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti–PD-1 Resistance in Head and Neck Cancer
2019 · Liye Zhou, Tenny Mudianto, et al. · Clinical Cancer Research · 266
ERK1/2 Regulation of CD44 Modulates Oral Cancer Aggressiveness
2011 · Nancy P. Judd, Ashley E. Winkler, et al. · Cancer Research · 222
Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance
2019 · Dhanya K. Nambiar, Todd Aguilera, et al. · Journal of Clinical Investigation · 177
PDF
Cutting Edge: IFN-Producing Cells Respond to CXCR3 Ligands in the Presence of CXCL12 and Secrete Inflammatory Chemokines upon Activation
2002 · Anne Krug, Ravindra Uppaluri, et al. · The Journal of Immunology · 160
Graph deep learning for the characterization of tumour microenvironments from spatial protein profiles in tissue specimens
2022 · Zhenqin Wu, Alexandro E. Trevino, et al. · Nature Biomedical Engineering · 152
PDF
Interferon-γ and Cancer Immunoediting
2005 · Gavin P. Dunn, Hiroaki Ikeda, et al. · Immunologic Research · 141
Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer
2023 · Kelsy C. Cotto, Yang-Yang Feng, et al. · Nature Communications · 130
PDF
TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response
2021 · Zexian Zeng, Cheryl J Wong, et al. · Nucleic Acids Research · 130
PDF
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer
2023 · Giacomo Oliveira, Ann Marie Egloff, et al. · Science Immunology · 123
PDF
Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus
2020 · Hisham Mehanna, John C Hardman, et al. · The Lancet Oncology · 119
A Surprising Cross-Species Conservation in the Genomic Landscape of Mouse and Human Oral Cancer Identifies a Transcriptional Signature Predicting Metastatic Disease
2014 · Michael D. Onken, Ashley E. Winkler, et al. · Clinical Cancer Research · 118
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
2021 · Glenn J. Hanna, Anne O'Neill, et al. · Clinical Cancer Research · 109
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers.
2008 · Ravindra Uppaluri, Gavin P Dunn, et al. · PubMed · 109
PDF
TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
2024 · Tetsuo Tani, Haritha Mathsyaraja, et al. · Cancer Discovery · 108
PDF
Works count: 708
Citation count: 11,390
H-index: 53
I10-index: 105
Year
Topic
Type